Brian Peter Zambrowicz
Direttore/Membro del Consiglio presso Texas A&M Institute for Genomic Medicine
Posizioni attive di Brian Peter Zambrowicz
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Texas A&M Institute for Genomic Medicine
 Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Brian Peter Zambrowicz
Precedenti posizioni note di Brian Peter Zambrowicz
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/1995 | 24/02/2015 |
| Fondatore | 07/07/1995 | 24/02/2015 | |
| NUEVOLUTION AB (PUBL) | Direttore/Membro del Consiglio | - | - |
| Corporate Officer/Principal | - | - |
Formazione di Brian Peter Zambrowicz
| University of Wisconsin | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Danimarca | 2 |
Posizioni
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Commercial Services |
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
